Mast has responded to the challenge of rapidly detecting carbapenemase resistance in Enterobacteriaceae with the development of Mast Uri Plate CRE.
Carbapenemases are clinically significant as they hydrolyse carbapenems and most other b-lactam antibiotics, severely limiting treatment options in critically ill patients. Thus, Mast has seen an increase in demand for the screening of such isolates from urine samples using the Mast Uri System.
This new test for use with the Mast Uri System gives a simple ‘Yes’ or ‘No’ answer within 24 hours directly from the urine specimen. If positive, the result can be confirmed with the Carbapenemase Detection Set (see page 82), in accordance with the published EUCAST and Public Health England (PHE) guidelines for the detection of these resistance mechanisms.
The Mast Uri System, implemented in many UK laboratories, now includes the
chromogenic Mast Uri Plate GBS for group B Streptococcus. In addition, a new Mast Uri Plate for yeast infections in immunocompromised patients is due later this year.
Further information is available from your local Mast representative or by email ([email protected]).